Professor Michael Ehrenstein details
Location:
- University College Hospital
GMC/GDC number:
3260874
Professional background
Professor Michael Ehrenstein is a consultant rheumatologist at UCLH since 1999. His key interests are in new therapies for rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus and other autoimmune rheumatic diseases. He leads the New Therapies Clinic for inflammatory arthritis at UCLH and has established with colleagues the Early Arthritis Clinic to enable rapid access for patients with rheumatoid arthritis. Michael studied medicine at the Middlesex Hospital, and trained in rheumatology at the Hammersmith Hospital and Addenbrooke’s Hospital, Cambridge.
He was previously an MRC clinician scientist at Cambridge University and the Laboratory of Molecular Biology. He was awarded a PhD at UCL on the pathogenesis of autoimmune rheumatic disease. He has undertaken many roles for NHS England, the British Society for Rheumatology, charities and universities within the realm of rheumatology and advised licensing authorities (MHRA) and commissioners regarding new therapies for arthritis.
Specialties
Research interests
Rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus
Publications
10 most recent publications (2021-2024):
1. Ibrahim, S.T., C.J. Edwards, M.R. Ehrenstein, B. Griffiths, C. Gordon, P. Hewins, D. Jayne, L. Lightstone, Z. McLaren, B. Rhodes, E.M. Vital, and J.A. Reynolds. 2024. Differences in management approaches for lupus nephritis within the UK. Rheumatol Adv Pract 8:rkae017.
2. Rivellese, F., A. Nerviani, G. Giorli, L. Warren, E. Jaworska, M. Bombardieri, M.J. Lewis, F. Humby, A.G. Pratt, A. Filer, N. Gendi, A. Cauli, E. Choy, I. McInnes, P. Durez, C.J. Edwards, M.H. Buch, E. Gremese, P.C. Taylor, N. Ng, J.D. Cañete, S. Raizada, N.D. McKay, D. Jadon, P.P. Sainaghi, R. Stratton, M.R. Ehrenstein, P. Ho, J.P. Pereira, B. Dasgupta, C. Gorman, J. Galloway, H. Chinoy, D. van der Heijde, P. Sasieni, A. Barton, C. Pitzalis, STRAP collaborative group 2023. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatology 5:e648-e659.
3. Shipa, M., L.R. Santos, D.X. Nguyen, A. Embleton-Thirsk, M. Parvaz, L.L. Heptinstall, R.J. Pepper, D.A. Isenberg, C. Gordon, and M.R. Ehrenstein. 2023. Identification of biomarkers to stratify response to B cell targeted therapies in a randomized trial for systemic lupus erythematosus. The Lancet Rheumatology 5: e24.-e35.
4. Szylar, G., R. Wysoczanski, H. Marshall, D.J.B. Marks, R. Jose, M.R. Ehrenstein, and J.S. Brown. 2022. A novel Streptococcus pneumoniae human challenge model demonstrates Treg lymphocyte recruitment to the infection site. Sci Rep 12:3990.
5. RA-MAP Consortia. 2022. RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients. Sci Data 9:196.
6. Arnold, J., S. Dass, S. Twigg, C.H. Jones, B. Rhodes, P. Hewins, M. Chakravorty, P. Courtney, M. Ehrenstein, M.Y. Md Yusof, and E.M. Vital. 2022. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. Rheumatology (Oxford)
7. Shipa, M.R.A., L. Langley, B. Sacks, S.A. Yeoh, M.D. Mainuddin, D. Mukerjee, M. Castelino, and M.R. Ehrenstein. 2022. Increased erythrocyte mean corpuscular volume by methotrexate predicts clinical response in psoriatic arthritis. Rheumatology (Oxford)61:e270-e273.
8. Shipa, M.R.A., S.A. Yeoh, A. Embleton-Thirsk, D. Mukerjee, and M.R. Ehrenstein. 2022. The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume. Rheumatology (Oxford)61:787-793.
9. Shipa, M., A. Embleton-Thirsk, M. Parvaz, L.R. Santos, P. Muller, K. Chowdhury, D.A. Isenberg, C.J. Doré, C. Gordon, M.R. Ehrenstein, on behalf of the BEATLUPUS Investigators. 2021. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial. Annals of Internal Medicine 174:1647-1657.
10. Shipa, M.R.A., R. Amarnani, S.A. Yeoh, M.D. Mainuddin, and M.R. Ehrenstein. 2021. Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy. Ann Rheum Dis 80:1628-1629.